Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 May 26;65(20):2211-21.
doi: 10.1016/j.jacc.2015.03.003. Epub 2015 Mar 15.

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

Robert W Yeh  1 , Dean J Kereiakes  2 , Philippe Gabriel Steg  3 , Stephan Windecker  4 , Michael J Rinaldi  5 , Anthony H Gershlick  6 , Donald E Cutlip  7 , David J Cohen  8 , Jean-Francois Tanguay  9 , Alice Jacobs  10 , Stephen D Wiviott  11 , Joseph M Massaro  12 , Adrian C Iancu  13 , Laura Mauri  14 ; DAPT Study Investigators
Affiliations
Randomized Controlled Trial

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

Robert W Yeh et al. J Am Coll Cardiol. .

Abstract

Background: The benefits and risks of prolonged dual antiplatelet therapy may be different for patients with acute myocardial infarction (MI) compared with more stable presentations.

Objectives: This study sought to assess the benefits and risks of 30 versus 12 months of dual antiplatelet therapy among patients undergoing coronary stent implantation with and without MI.

Methods: The Dual Antiplatelet Therapy Study, a randomized double-blind, placebo-controlled trial, compared 30 versus 12 months of dual antiplatelet therapy after coronary stenting. The effect of continued thienopyridine on ischemic and bleeding events among patients initially presenting with versus without MI was assessed. The coprimary endpoints were definite or probable stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE). The primary safety endpoint was GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries) moderate or severe bleeding.

Results: Of 11,648 randomized patients (9,961 treated with drug-eluting stents, 1,687 with bare-metal stents), 30.7% presented with MI. Between 12 and 30 months, continued thienopyridine reduced stent thrombosis compared with placebo in patients with and without MI at presentation (MI group, 0.5% vs. 1.9%, p < 0.001; no MI group, 0.4% vs. 1.1%, p < 0.001; interaction p = 0.69). The reduction in MACCE for continued thienopyridine was greater for patients with MI (3.9% vs. 6.8%; p < 0.001) compared with those with no MI (4.4% vs. 5.3%; p = 0.08; interaction p = 0.03). In both groups, continued thienopyridine reduced MI (2.2% vs. 5.2%, p < 0.001 for MI; 2.1% vs. 3.5%, p < 0.001 for no MI; interaction p = 0.15) but increased bleeding (1.9% vs. 0.8%, p = 0.005 for MI; 2.6% vs. 1.7%, p = 0.007 for no MI; interaction p = 0.21).

Conclusions: Compared with 12 months of therapy, 30 months of dual antiplatelet therapy reduced the risk of stent thrombosis and MI in patients with and without MI, and increased bleeding. (The Dual Antiplatelet Therapy Study [The DAPT Study]; NCT00977938).

Keywords: acute coronary syndromes; antiplatelet therapy; myocardial infarction; percutaneous coronary intervention; randomized clinical trial.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Enrollment, randomization and follow-up of patients in the DAPT Study stratified by acute myocardial infarction status at presentation
Patients were enrolled within 72 hours after placement of either a bare metal or drug-eluting stent, and received open-label treatment with aspirin and thienopyridine. Eligible subjects were then randomized to thienopyridine or placebo, while continuing aspirin, and followed for an additional 18 months (months 12–30).
Figure 2
Figure 2. Cumulative incidence of stent thrombosis according to randomization arm for patients with (Panel A) and without (Panel B) acute myocardial infarction
Randomization occurred 12 months after initial presentation. Endpoint includes definite or probable stent thrombosis as assessed according to the criteria of the Academic Research Consortium. The effect of continued thienopyridine on stent thrombosis was similar for patients with vs. without myocardial infarction at presentation (interaction p=0.69).
Figure 3
Figure 3. Cumulative incidence of major adverse cardiovascular and cerebrovascular events (MACCE) according to randomization arm for patients with (Panel A) and without (Panel B) acute myocardial infarction
MACCE was defined as the composite of death, myocardial infarction or stroke. Randomization occurred 12 months after initial presentation. The effect of continued thienopyridine on MACCE was greater for patients with MI compared with patients without myocardial infarction at presentation (interaction p=0.03).
Figure 4
Figure 4. Cumulative incidence of myocardial infarction according to randomization arm for patients with (Panel A) and without (Panel B) acute myocardial infarction
Randomization occurred 12 months after initial presentation. The effect of continued thienopyridine on myocardial infarction was similar for patients with vs. without myocardial infarction at presentation (interaction p=0.15).
See this image and copyright information in PMC

Comment in

References

    1. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine. 2014;371:2155–2166. - PMC - PubMed
    1. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European heart journal. 2015 [epub ahead of print] - PubMed
    1. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. Journal of the American College of Cardiology. 2009;53:1399–1409. - PubMed
    1. Authors/Task Force m. Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) European heart journal. 2014;35:2541–2619. - PubMed
    1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Journal of the American College of Cardiology. 2011;58:e44–e122. - PubMed

Publication types

Associated data